Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$122.98
-5.9%
$140.68
$122.77
$238.00
$18.00B0.011.32 million shs3.09 million shs
Eisai Co., Ltd. stock logo
ESALY
Eisai
$61.51
-2.1%
$61.51
$36.88
$73.90
$17.64B0.3160,916 shs331,800 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$737.56
-6.5%
$848.36
$711.40
$972.53
$699.33B0.343.32 million shs5.29 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$135.28
-5.5%
$146.31
$135.23
$159.64
$35.72B0.717.55 million shs21.34 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-5.91%-11.12%-14.46%-19.20%-40.41%
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.00%0.00%0.00%0.00%0.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-6.47%-10.09%-20.70%-5.68%-4.99%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
-5.48%-6.39%-9.62%-2.65%-6.08%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biogen Inc. stock logo
BIIB
Biogen
4.8409 of 5 stars
4.25.00.03.73.42.51.9
Eisai Co., Ltd. stock logo
ESALY
Eisai
N/AN/AN/AN/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8976 of 5 stars
3.45.03.34.03.22.51.9
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.42
Hold$213.3373.47% Upside
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.00
N/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.7236.90% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.77
Moderate Buy$135.28N/A

Current Analyst Ratings Breakdown

Latest BIIB, LLY, XLV, and ESALY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2025
Biogen Inc. stock logo
BIIB
Biogen
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/18/2025
Biogen Inc. stock logo
BIIB
Biogen
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$138.00 ➝ $135.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$244.00 ➝ $224.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$156.00 ➝ $139.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$281.00 ➝ $245.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$192.00 ➝ $157.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$160.00 ➝ $145.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$231.00 ➝ $225.00
2/13/2025
Biogen Inc. stock logo
BIIB
Biogen
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $140.00
(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.68B1.86$20.19 per share6.09$114.71 per share1.07
Eisai Co., Ltd. stock logo
ESALY
Eisai
$6.74B2.62$2.68 per share22.94$23.94 per share2.57
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B15.53$12.02 per share61.34$15.05 per share49.01
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$11.1910.997.451.5116.87%14.98%8.76%4/23/2025 (Estimated)
Eisai Co., Ltd. stock logo
ESALY
Eisai
$426.79M$0.8770.7051.692.464.11%3.86%2.50%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7162.9923.701.4023.51%85.24%16.19%5/1/2025 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A29.15N/AN/AN/AN/AN/A

Latest BIIB, LLY, XLV, and ESALY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
4/23/2025N/A
Biogen Inc. stock logo
BIIB
Biogen
$3.59N/AN/AN/A$2.25 billionN/A
2/12/2025Q4 2024
Biogen Inc. stock logo
BIIB
Biogen
$3.43$3.44+$0.01$1.83$2.42 billionN/A
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Eisai Co., Ltd. stock logo
ESALY
Eisai
$0.881.43%N/A101.15%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.81%+15.21%51.24%11 Years
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.341.73%N/AN/AN/A

Latest BIIB, LLY, XLV, and ESALY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/9/2025
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$0.56453/24/20253/24/20253/26/2025
1/9/2025
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$0.56453/24/20253/24/20253/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.27
1.35
0.90
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.10
2.20
1.77
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Eisai Co., Ltd. stock logo
ESALY
Eisai
0.03%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.16%
Eisai Co., Ltd. stock logo
ESALY
Eisai
N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
8,720146.38 million146.14 millionOptionable
Eisai Co., Ltd. stock logo
ESALY
Eisai
11,322286.77 millionN/ANot Optionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A264.07 millionN/ANot Optionable

Recent News About These Companies

XLV: My Method For Navigating These Pullbacks
Health Care Sector Trying to Bounce Back
Time for Defensive Sector ETFs?
Health Care Has Been a Top Sector
Final Trade: FWONK, XLV, MSFT, PEP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biogen stock logo

Biogen NASDAQ:BIIB

$122.98 -7.73 (-5.91%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$122.50 -0.48 (-0.39%)
As of 04/4/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Eisai stock logo

Eisai OTCMKTS:ESALY

$61.51 -1.33 (-2.11%)
As of 01/30/2023

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$737.56 -51.53 (-6.53%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$717.25 -20.31 (-2.75%)
As of 04/4/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$135.28 -7.85 (-5.48%)
Closing price 04/4/2025 04:10 PM Eastern
Extended Trading
$134.88 -0.40 (-0.29%)
As of 04/4/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.